Atlas Trials

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

Clinical trial NCT03558139 · COMPLETED

Trial details

NCT number
NCT03558139
Sponsor
Gilead Sciences
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Ovarian Cancer
Start date
2018-05-23
Primary completion
2020-12-03
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.